PRAXIS BIORESEARCH, LLC
Biotech · Private
PRX-P4-003, a novel dopaminergic prodrug for treating apathy in Alzheimer's Disease
- Grants
- $4.5M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 3
- 2 granted · 1 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201820192020202120222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Validating Prodrug PRX-P4-003 approach in humans by phase 0 microdose study | $300,139 | |
| Federal grant | Department of Health and Human Services · Phase II · Validating Prodrug PRX-P4-003 approach in humans by phase 0 microdose study | $662,269 | |
| Federal grant | Department of Health and Human Services · Phase II · Validating Prodrug PRX-P4-003 approach in humans by phase 0 microdose study | $58,914 | |
| Federal grant | Department of Health and Human Services · Phase II · Validating Prodrug PRX-P4-003 approach in humans by phase 0 microdose study | $535,295 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Dopaminergic Stimulant Prodrug for the Treatment of Apathy in AD | $448,752 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Dopaminergic Stimulant Prodrug for the Treatment of Apathy in AD | $1,451,070 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Dopaminergic Stimulant Prodrug for the Treatment of Apathy in AD | $957,571 | |
| Federal grant | Department of Health and Human Services · Phase II · Novel Dopaminergic Stimulant Prodrug for the Treatment of Apathy in AD | $50,000 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2430 | STELLULAR BIO, INC. | — | — |
| 2431 | SYNTHETIC VECTOR DESIGNS, LLC | — | — |
| 2432 | GLSYNTHESIS, INC. | — | — |
| 2433 | PRAXIS BIORESEARCH, LLC | — | — |
| 2434 | Coactigon, Inc. | — | — |
| 2435 | SPIRIFY PHARMA INC | — | — |
| 2436 | ENDURX PHARMACEUTICALS, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Prodrugs Of Fencamfaminegranted
- Prodrugs Of Fencamfaminegranted
- Prodrugs Of Fencamfamineapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.